Characteristicsa | Valid cases | Norwegians (n=299) | South Asians (n=57) | Othersb(n=24) | Pc |
---|---|---|---|---|---|
Age- and gender adjusted last available measure of risk factors for CVD (mean, 95% CI) | |||||
HbA1c, % | 360 | 7.0 (6.84-7.13) | 7.9 (7.48-8.28) | 7.5 (6.96-8.08) | <0.001 |
SBP, mmHg | 356 | 135.5 (136.3-140.7) | 134.3 (128.8-139.8) | 138.9 (131–146.7) | 0.370 |
DBP, mmHg | 356 | 78.7 (77.6-79.8) | 73.7 (70.9-76.4) | 72.5 (68.6-76.4) | <0.001 |
Total chol, mmol/L | 349 | 4.7 (4.58-4.83) | 4.6 (4.30-4.87) | 4.8 (4.40-5.25) | 0.596 |
LDL-chol, mmol/L | 231 | 2.7 (2.59-2.88) | 2.6 (2.30-2.95) | 2.8 (2.21-3.34) | 0.817 |
HDL-chol, mmol/L | 332 | 1.3 (1.27-1.36) | 1.2 (1.07-1.26) | 1.2 (1.10-1.37) | 0.013 |
Total chol/HDL-chol | 332 | 3.7 (3.60-3.88) | 4.1 (3.80-4.41) | 4.1 (3.67-4.58) | 0.049 |
Age- and gender adjusted proportion receiving pharmacological therapy (%, 95% CI) | |||||
Glucose lowering | 380 | 73.8 (68.5-79.0) | 96.5 (91.7-101.3) | 87.9 (75.0-100.9) | <0.001 |
Anti-hypertensive | 380 | 91.1 (87.8-94.4) | 86.6 (77.4-95.9) | 80.7 (64.9-96.5) | 0.345 |
Lipid-lowering | 380 | 66.3(60.4-72.1) | 60.7(46.1-75.3) | 67.5(47.5-87.5) | 0.781 |
Age- and gender adjusted proportions not achieving treatment targets among patients receiving pharmacological therapy (%, 95% CI) | |||||
HbA1c >7.5% | 280 | 26.0 (19.4-32.6) | 47.2 (31.4- 63.0) | 39.6 (16.3-62.9) | 0.031 |
SBP > 140 mmHg | 319 | 35.5 (29.5-41.5) | 22.3 ( 7.7 – 36.8) | 56.1 (32.2 – 80.0) | 0.050 |
DBP > 85 mmHg | 319 | 16.5 (12.0-21.1) | 12.2 (2.3-22.1) | 11.6 (−3.6-26.7) | 0.645 |
Total Chol/HDL chol ≥ 4.0 | 226 | 31.8 (24.8-39.0) | 43.8 (27.6-59.9) | 28.5 (7.1 – 50.0) | 0.378 |